Bulletin
Investor Alert

New York Markets After Hours

Market Pulse Archives

Feb. 17, 2016, 8:26 a.m. EST

Regulus Therapeutics stock surges after 'promising' Hep C drug trial results

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regulus Therapeutics Inc. (RGLS)

or Cancel Already have a watchlist? Log In

By Emma R. Court

RGLS

Regulus Therapeutics Inc. /zigman2/quotes/202916513/composite RGLS +0.60% stock surged nearly 40% in active pre-market trade Wednesday after the company reported positive results from a phase 2 study of a Hepatitis C treatment. Regulus said it will accelerate the Hepatitis C drug's development, given what CEO and President Paul Grint called its "promising potential to shorten treatment regimens." The company's RG-101 drug was injected at the beginning and end of the four-week treatment regimen, with patients also taking anti-viral agents throughout the month-long period. Nearly all of the 38 patients evaluated through eight weeks of follow-up saw the Hepatitis C virus reduced to very low levels, and all the patients saw the same result through 12 weeks of follow-up. Additional results from all 79 patients in the trial should emerge late in the second quarter, the company said.

/zigman2/quotes/202916513/composite
US : U.S.: Nasdaq
$ 1.69
+0.01 +0.60%
Volume: 25,848
Nov. 28, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$28.29 million
Rev. per Employee
N/A
loading...

Get news alerts on Regulus Therapeutics Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.